BRAF and neoplasm: We assayed the cell viability against dinaciclib (henceforth referred as CDK2i) in a panel of 11 BRAF‐mutated cell lines, including two PDX‐derived cell pairs, obtained before BRAFi treatment, M026.X1.CL and M029.X1.CL, and after treatment, upon tumor relapse, M026R.X1.CL and M029R.X1.CL, respectively (Fig 4A; Possik et al, 2014; Kemper et al, 2016).